Company profile: Guide Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology solutions addressing delivery of genetic therapies, leveraging patented technologies to test thousands of chemically distinct nanoparticles in vivo to identify simple, scalable, clinically relevant nanoparticles that target new cell types efficiently and safely.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Guide Therapeutics
Amyris
HQ: United States
Website
- Description: Provider of biotech chemical products made via advanced sugarcane-derived fermentation. Portfolio includes Neossance Squalane for cosmetics and skincare moisturization and barrier repair; Artemisinic Acid used in antimalarial treatments; Biosilica from sugarcane ashes for cosmetics; Neossance Hemisqualane as a plant-based silicone alternative; Biofene renewable specialty chemical building block; RealSweet Reb M zero-calorie sweetener.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amyris company profile →
Cepheid
HQ: United States
Website
- Description: Provider of accurate, easy-to-use molecular diagnostic systems and tests that automate complex procedures for institutions of any size. Offerings include the GeneXpert System and single-use Xpert cartridges for nucleic acid extraction, amplification, and detection, plus Xpert Xpress PCR tests for Strep A, SARS-CoV-2, CoV-2/Flu/RSV, and Flu A/B.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cepheid company profile →
SoftGenetics
HQ: United States
Website
- Description: Provider of genetic analysis software for researchers and clinicians, including Mutation Surveyor for Sanger DNA variant detection with custom reporting and user management; NextGENe for NGS SNP/indel, structural variant and transcriptome analysis; Geneticist Assistant for NGS variant interpretation, tracking and coverage confirmation; GeneMarker/HTS/MTP for genotyping, forensic NGS and multiple template processing, compatible with major sequencing systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SoftGenetics company profile →
Tune Therapeutics
HQ: United States
Website
- Description: Provider of an epigenetic programming platform for disease treatment, offering TEMPO to control gene activity without altering DNA sequence by activating, silencing, or fine-tuning gene output, and TUNE-401, an investigational HBV therapy that epigenetically silences viral DNA in host chromosomes and cccDNA to pursue a functional cure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tune Therapeutics company profile →
Palamedrix
HQ: United States
Website
- Description: Provider of a multi-omic platform leveraging DNA nanotechnology to deliver comprehensive data for biomedical applications, accelerating advancements in life science and medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Palamedrix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Guide Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Guide Therapeutics
2.2 - Growth funds investing in similar companies to Guide Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Guide Therapeutics
4.2 - Public trading comparable groups for Guide Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →